Compare Enveric Biosciences Inc (ENVB) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Redwire Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Redwire Corporation trades at $9.89 (market cap $2.56B). The key difference: Redwire Corporation is far larger — about 382.7× Enveric Biosciences Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Redwire Corporation for 18 Days on average.
| ENVB | RDW | |
|---|---|---|
Market Cap | $6.69M | $2.56B |
Volume | 41,141 | 14,037,053 |
Sector | Health | Industrials |
52-Week High | $10.80 | $25.90 |
52-Week Low | $1.27 | $5.06 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | -$1.60M | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Redwire Corporation (RDW) trades at $10.24, down 3.58% with bearish technical signals despite 80% analyst buy ratings. The company shows strong revenue growth (89.6% YoY in Q2 2026) but faces profitability challenges with negative net margins (-57.26%) and consecutive earnings misses. Recent Space Force contract wins and partnerships highlight growth potential in the expanding space infrastructure market, though cash flow remains negative from operations.
The stock presents a high-risk growth opportunity with significant upside to the $14.88 consensus target if execution improves, but persistent losses and dependence on SpaceX's Starship timeline create substantial volatility. Investors must weigh strong institutional support against fundamental weaknesses in a speculative sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
